MediciNova, Inc.

Contributing Author

Recent Articles by MediciNova, Inc.

15 hours	MediciNova to Participate in the Maxim Growth Summit MNOV -5.98% GlobeNewswire
Sep-28	MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) MNOV -18.60% GlobeNewswire
Sep-24	MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) MNOV -5.36% GlobeNewswire
Sep-08	MediciNova to Participate in Two Investor Conferences in September MNOV +7.36% GlobeNewswire
Jul-15	MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients MNOV GlobeNewswire
Jun-30	MediciNova CEO Provides Shareholder Update MNOV GlobeNewswire
Jun-08	MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment MNOV GlobeNewswire
May-26	MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) MNOV GlobeNewswire
Apr-27	New Peer-Reviewed Study Reveals Actionable Immune-Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation MNOV GlobeNewswire
Mar-16	MediciNova to Participate at the 38th Annual ROTH Conference MNOV +7.41% GlobeNewswire
Jan-29	MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients MNOV GlobeNewswire
Jan-06	2026 New Year's Greetings from the CEO MNOV GlobeNewswire
Dec-18	MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy MNOV GlobeNewswire
Dec-08	MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND MNOV GlobeNewswire
Dec-01	Message from the CEO to MediciNova Shareholders MNOV GlobeNewswire
Nov-18	MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor MNOV GlobeNewswire
Nov-06	MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards MNOV -7.28% GlobeNewswire
Nov-04	MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) MNOV -5.33% GlobeNewswire
Oct-30	MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication MNOV MNOV +39.50% GlobeNewswire
Oct-06	MediciNova to Present at the LD Micro Main Event XIX Investor Conference MNOV GlobeNewswire
Sep-22	MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) MNOV GlobeNewswire
Sep-16	MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND MNOV GlobeNewswire
Sep-08	MediciNova Provides Shareholder Update on Key Developments MNOV GlobeNewswire
Sep-03	MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference MNOV GlobeNewswire
Aug-26	MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial MNOV GlobeNewswire
Jul-31	MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million MNOV MNOV +7.92% GlobeNewswire
Jul-24	MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials MNOV GlobeNewswire

MediciNova, Inc.

Recent Articles by MediciNova, Inc.

Upgrade your Finviz experience